GROUP ONE TRADING, L.P. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 138 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.

Quarter-by-quarter ownership
GROUP ONE TRADING, L.P. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$351,937
+89.2%
9,213
+78.7%
0.00%0.0%
Q2 2023$185,977
+367.8%
5,156
+395.3%
0.00%
Q1 2023$39,756
-73.7%
1,041
-89.3%
0.00%
-100.0%
Q3 2019$151,000
-55.8%
9,752
-58.3%
0.00%
-66.7%
Q4 2018$342,000
-76.7%
23,364
-71.1%
0.00%
-75.0%
Q3 2018$1,467,000
+85.2%
80,733
+71.9%
0.01%
+71.4%
Q2 2018$792,000
+89.0%
46,976
+119.8%
0.01%
+75.0%
Q1 2018$419,000
-21.2%
21,372
-51.5%
0.00%
-33.3%
Q3 2016$532,000
+9.7%
44,038
-21.6%
0.01%0.0%
Q2 2016$485,000
-13.1%
56,181
-4.7%
0.01%
-25.0%
Q1 2016$558,000
-78.7%
58,962
-60.9%
0.01%
-74.2%
Q4 2015$2,616,000
+4.3%
150,966
-19.2%
0.03%
-11.4%
Q3 2015$2,509,000
-14.9%
186,787
+43.0%
0.04%
-14.6%
Q2 2015$2,950,000
+71.8%
130,655
+8.7%
0.04%
+51.9%
Q1 2015$1,717,000
+2019.8%
120,247
+1334.4%
0.03%
+2600.0%
Q4 2014$81,000
-84.5%
8,383
-84.2%
0.00%
-87.5%
Q2 2014$524,000
-13.7%
53,064
+11.0%
0.01%
-20.0%
Q1 2014$607,000
-80.2%
47,789
-76.7%
0.01%
-78.3%
Q4 2013$3,073,000
+36.6%
204,984
+0.6%
0.05%
+7.0%
Q3 2013$2,249,000
+254.2%
203,727
+155.1%
0.04%
+168.8%
Q2 2013$635,00079,8700.02%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2015
NameSharesValueWeighting ↓
Third Security, LLC 14,092,771$206,177,00028.12%
BB BIOTECH AG 8,322,860$121,763,0003.90%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 398,633$4,579,0002.84%
DOHENY ASSET MANAGEMENT /CA 227,193$3,324,0002.43%
SNYDER CAPITAL MANAGEMENT L P 2,833,759$41,458,0002.24%
First Light Asset Management, LLC 938,399$13,729,0002.19%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,027,164$132,067,0001.77%
Taylor Wealth Management Partners 204,277$2,989,0001.72%
Sterling Global Strategies LLC 22,000$321,860,0001.63%
Granite Investment Partners, LLC 988,939$14,468,0001.06%
View complete list of HALOZYME THERAPEUTICS INC shareholders